Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/- binimetinib or alpelisib.

ABSTRACT:

Background

Treatment strategies inhibiting BRAF in combination with EGFR have been developed in patients with BRAF^V600E mutant metastatic colorectal cancer, but intrinsic and secondary resistance remains a challenge. We aimed to investigate which genetic alterations cause intrinsic non-response and/or acquired resistance in these patients receiving therapies consisting of a backbone of BRAF and EGFR inhibition.

Methods

This was a cohort study on genetic alterations in patients with BRAF^V600E mutant advanced colorectal cancer treated with inhibitors of the MAPK pathway. We examined tumour tissue for genetic alterations at baseline, during treatment and at progression.

Results

In total, 37 patients were included in this cohort. Genetic alterations

SUBMITTER: Huijberts SCFA 

PROVIDER: S-EPMC7782586 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature